Kraig Labs has brought onboard two experts in business to assist them with the marketing of their new products. Raymond Kutsunai, the former general manager of SmithKline & French Laboratories, Japan, and SmithKline Beecham's former CEO and Chairman Henry Wendt have joined the board of advisors. Here are some videos that explain why this company is worth investing in:

So I thought I would try my hand at some penny stocks and saw this one recommended in an email. The price was floating around .25 and the company announced a 9 to 1 stock split. I bought 1000 shares at .255 and ended up with 10k shares worth .0255. If I had done my homework on this I would have seen that the company is basically a one man show with no revenue. Now its trading around .014. This stock [...]

Position: 100 shares Avg. Price: $26.60 This was a buy near recent lows and also a play to capture the dividend ($47.50 for 100 shares). My target is the downtrend line from the Dec 07 high. It is around $28.90 at the present time. Earnings are due out in a couple of weeks. If it runs up prior to earnings I will most likely take it off then. Sold @$27.00 prior to earnings. I did not want to [...]

Position: 700 shares Avg. Price: $3.48 This position is a long term trade. My thoughts were to buy it when it dipped close to where the government bought in and then add as it went up. My outlook is that C will grow at some point and maybe this position will be ready to cash out 10 or so years down the road. I see it as a defined risk, similar to an option. My full position will be 1000 shares [...]